Imatinib-induced Dental Hyperpigmentation in Childhood Chronic Myeloid Leukemia

Abstract

ribosomal structural protein RPS19 or transducer of erythropoietin signaling JAK2 tyrosine kinase in normal blood or in DBA. It remains to be determined whether epigenetic silencing by histone modifications plays a role in DBA as hinted by a report of a remission in a DBA patient induced by a histone deacetylase inhibitor valproic acid. 10 ACKNOWLEDGMENT

Imatinib mesylate–induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors

“…In a 13-year-old child with CML, hyperpigmentation of the face, teeth, and gums developed after 6 months of imatinib mesylate treatment. 44 Similarly, a 40-year-old Indian man with CML developed nail hyperpigmentation during imatinib mesylate therapy. 45 The paradoxical repigmentation noted in this patient is intriguing, although the mechanism remains speculative.…”

Imatinib‐induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature

“…To the best of our knowledge, 30 cases of well‐documented imatinib‐related hyperpigmentation were described in literature and included in our review (Table ) . Cases characterized by pigmentary changes localized only in body areas previously affected by rash and/or pruritus were excluded due to the possibility of a post‐inflammatory hyperpigmentation.…”

Drug-induced hair colour changes

“…In the majority of cases, the pigmentary abnormalities were reversible after dose reduction or drug withdrawal. Localized or diffuse skin depigmentation has been observed in 15-25% of patients [32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48], and cases of cutaneous [31,32,37,44,45], nail [40,42,47], or gingival [42,43,47] hyperpigmentation have been described. The fact that such adverse events are relatively frequent and dose-dependent suggests that they are due to a direct pharmacological effect of imatinib.…”